



Early View

Invited review

Lung cancer in patients with fibrosing interstitial lung diseases – An overview of current knowledge and challenges

Namrata Kewalramani, Carlos Machahua, Venerino Poletti, Jacques Cadranel, Athol U Wells, Manuela Funke-Chambour

Please cite this article as: Kewalramani N, Machahua C, Poletti V, *et al.* Lung cancer in patients with fibrosing interstitial lung diseases – An overview of current knowledge and challenges. *ERJ Open Res* 2022; in press (<https://doi.org/10.1183/23120541.00115-2022>).

This manuscript has recently been accepted for publication in the *ERJ Open Research*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.

Copyright ©The authors 2022. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Lung cancer in patients with fibrosing interstitial lung diseases

– An overview of current knowledge and challenges

Namrata Kewalramani¹, Carlos Machahua^{1,2}, Venerino Poletti³, Jacques Cadranel⁴, Athol U Wells⁵,

Manuela Funke-Chambour^{1,2}

¹*Department for BioMedical Research DBMR, Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.*

²*Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.*

³*Department of Thoracic Diseases, "GB. Morgagni" Hospital, Forlì, Dipartimento di Medicina Specialistica Diagnostica e Sperimentale (DIMES) University of Bologna, Italy*

⁴*Department of Pulmonary Medicine and Thoracic Oncology; Constitutive Reference Center of Rare Pulmonary Diseases, AP-HP, Hôpital Tenon and GRC04 Theranoscan, Sorbonne Université, Paris 75970, France*

⁵*Royal Brompton and Harefield NHS Foundation Trust, London, UK; National Heart and Lung Institute, Imperial College London, London, UK*

Corresponding author:

Manuela Funke-Chambour, MD

Department of Pulmonary Medicine

University Hospital Bern, Bern University, Switzerland

Phone: +41 31 632 82 34

Fax: +41 31 632 14 04

Email: manuela.funke-chambour@insel.ch

Abbreviations

AE	Acute exacerbation
CTD-ILD	Connective Tissue Disease associated ILD
COPD	Chronic obstructive pulmonary disease
CPFE	Combined pulmonary fibrosis and emphysema
DLCO	Diffusing capacity for carbon monoxide
fILD	fibrotic ILD
FVC	Forced vital capacity
GAP	Gender-Age-Physiology
ICI	Immune Checkpoint inhibitors
ILD	Interstitial lung diseases
IPF	Idiopathic Pulmonary Fibrosis
KI	Kinase Inhibitors
LC	Lung cancer
nab-paclitaxel	nanoparticle albumin-bound paclitaxel
NSCLC	Non small cell Lung Cancer
RFA	Radio Frequency Ablation
SASP	Senescence Associated Secretory Phenotypes
SBRT	Stereotactic Body Radiation Therapy
UIP	Usual Interstitial Pneumonia pattern

Abstract

Patients with progressive fibrosing interstitial lung diseases (fILD) have increased morbidity and mortality. Lung fibrosis can be associated with lung cancer (LC). The pathogenesis of both diseases shows similarities although not all mechanisms are understood.

The combination of the diseases is challenging, due to its amplified risk of mortality and also because lung cancer treatment carries additional risks in patients with underlying lung fibrosis.

Acute exacerbations in fILD patients are linked to increased mortality and the risk of acute exacerbations is increased after LC treatment with surgery, chemotherapy, or radiotherapy.

Careful selection of treatment modalities is crucial to improve survival whilst maintaining acceptable quality of life in patients with combined LC and fILD.

This overview of epidemiology, pathogenesis, treatment, and a possible role for antifibrotic drugs in patients with LC and fILD is the summary of a session presented during the virtual ERS conference 2021. The review summarises current knowledge and identifies areas of uncertainty. Most current data relate to patients with combined idiopathic pulmonary fibrosis and LC. There is a pressing need for additional prospective studies, required for the formulation of a consensus statement or guideline on the optimal care of patients with LC and fILD.

Introduction

Interstitial lung diseases (ILD) are characterised by pathological changes in the pulmonary parenchyma, sometimes triggered by inflammation but sometimes with an epithelial-fibrotic pathogenesis, in which inflammation is believed to play little part. Idiopathic Pulmonary Fibrosis (IPF) is the most common type of fibrosing ILD (fILD), almost always progresses (at a highly variable rate) and has the worst prognosis. A histological pattern of usual interstitial pneumonia pattern (UIP) can be diagnostic for IPF in absence of other causes. A definite UIP pattern on CT is reliably predictive of a UIP pattern as biopsy and is characterised by honeycombing, reticulation, traction bronchiectasis, and subpleural and basal predominance [1]. A UIP pattern in IPF and other disorders tends to progress [2]. Other fILD can develop a progressive phenotype. Once progression despite management has occurred, the disease course is usually similar to IPF [3]. Acute exacerbations (AE) are acute flares of ILD, sometimes overtly triggered e.g. by infection, surgery and associated with high short-term mortality [4]. AE can also increase mortality in patients with other fILD [5]. Antifibrotic drugs have been approved for IPF and, recently, for other progressive fILD that decelerate disease progression and thus increase survival [1, 6–8]. Increased survival due to delayed disease progression in IPF and other progressive fILD patients leads to an increased prevalence of comorbidities and complications, with their optimal management complicated by concurrent ILD. Lung cancer (LC) as a comorbidity in ILD patients is the focus of the present review.

i. Epidemiology and Risk factors of Lung cancer in ILD patients

LC is an important comorbidity encountered in ILD patients, especially in IPF [9]. In some statements, confusion has arisen due to failure to distinguish between prevalence, incidence, and cumulative incidence. In the following summary, we present an overview of current knowledge, emphasising the importance of these distinctions. LC prevalence refers to the total number of people suffering from LC at a single point in time in a study population [10], LC incidence refers to the rate of development of new cases during a short time period (usually expressed as annual incidence) [10]. LC cumulative incidence is the total proportion of patients developing LC during a prolonged period of time (e.g. five years) [11].

Prevalence

A review by Ballester et al. reported prevalences of LC in IPF ranges from 2.7% to 48% and is significantly higher than in the general population [12]. A meta-analysis has shown difference by region in prevalence of LC in fILD. The prevalence in Asian cohorts is 15.3 % and European cohort is 11.6% [13].

Incidence

Overall cancer incidence in IPF was 290 cases per 10,000 person years in a population-based cohort study from Korea with 25,241 IPF patients and 75,723 matched controls. Risk for LC was the highest followed by lymphoma and skin [14]. In a study from the UK studying incidence of LC in IPF, there was an increased incidence compared to the general population (rate ratio of 4.99) due to a marked increase of lung cancer incidence in IPF patients (112 per 10,000 person years in IPF compared to 22.9 per 10,000 person years in the general population) [15]. A study from the US found the incidence of LC in IPF was 3.34-fold higher than in the general population who developed LC [16]. This study also compared cancer laterality, primary site, histology and stage. They found statistically significant difference in LC in IPF as compared LC in a general population. This suggest that LC in IPF is phenotypically distinctive from “sporadic” LC [16]. However, in patients with ILD and rheumatoid arthritis, polymyositis/dermatomyositis or systemic sclerosis the increase was as high as 4.95-fold [16]. Lung cancer origin and consequence can be additionally confounded in face of risk factors such as smoking [17], silica and asbestos [18]. The histopathological UIP fibrosis pattern predisposes to pulmonary cancerous lesions [19]. Also, genetic factors, contributing to cancer susceptibility and also predisposing to IPF, include *SFTPA1* and *SFTPA2* [20].

Cumulative incidence

The cumulative cancer incidence rises strikingly with longer follow-up in IPF patients. In one study, the incidence of LC was 1.1% at 1 year, 8.7% at 3 years, 15.9% at 5 years and 31.1% at 10 years [21]. A nationwide population-based study in Korea found the prevalence of LC in IPF cases to be 6.4%. The median time from diagnosis of IPF to LC development was 16.3 months [23]. The cumulative incidence of LC in IPF increases from 1.7% at 1 year, 4.7% at 3 years and 7% at 5 years [22]. The incidence of LC is increased in patients with ILD and COPD, but even more in patients with IPF or COPD and ILD [23].

Risk factors for cancer in fibrotic ILD are older age at diagnosis [24], smoking [24–28], male gender [25–28], IPF per se (adjusted for age, gender, and smoking) [14], rapid annual decline in FVC and low DLCO [26, 28] as well as emphysema [27, 28].

ii. Disease Characteristics and Prognosis of Lung cancer in ILD patients

Lung cancer in IPF patients (LC-IPF) occurs more frequently in the lower lobes ($p < 0.001$), whereas non-IPF ILD patients do not differ in localisation to LC in the general population [16]. A clinicopathological study in Japan divided histological sub-groups into UIP (clinically IPF group), non UIP (clinically non-IPF ILD) and a normal group (without ILD) and showed that patients with LC and UIP on histology had a subpleural LC predilection in the lower lobes (75.5%), matching the typical distribution of UIP [19]. The most frequent cancer type was squamous cell cancer (62.8%) [19]. In comparison, in the non-UIP group, LC occurred most frequently in the upper lobes (68.1%), with adenocarcinoma the commonest cancer type (55.2%) [19].

The occurrence of cancer within the fibrotic regions was confirmed by another study, in which LC localisation within fibrotic areas was seen in 50%, followed by marginal-fibrotic areas (29%), and extra fibrotic areas (13%) [29]. Radiologically, LC is most often found on CT in areas within fibrosis (44.4%) followed by adjacent areas abutting fibrosis (29.6%) [21].

In a large multi-centre Greek cohort ($n=1016$), LC-IPF included squamous cell carcinoma in 34.3%, adenocarcinoma in 27.5% and small cell lung carcinoma (SCLC) in 14.7% in histological samples [30]. Again, 57% of patients had cancer within the lower lobes [30]. Squamous cell carcinoma was confirmed as the most frequent histopathological type in other studies [31]. Cancer-type distributions with squamous cell cancer in 37.8%, adenocarcinoma in 30.8% were found in a meta-analysis of a total of 131,947 IPF patients with 6384 with LC from 8 different countries [32].

Survival differences between IPF without LC and IPF with LC were statistically significant ($p < 0.001$) [16], with lower survival over time for those with IPF and cancer [16, 27, 33]. A single centre retrospective study found an increased mortality in patients with connective tissue disease associated ILD with LC as compared to those without LC [28].

Both the histological cancer type and its stage influences survival in patients with IPF, as in the general LC population. Depending on the histological type and stage outcome in IPF patients can be additionally impacted. In a recently published study in patients with LC, LC-IPF patients had a poorer prognosis than a control group of LC patients (5-year survival rate: 14.5% vs. 30.1%, $P < 0.001$) [34]. The IPF sub-group had a worse prognosis than the group without IPF among patients with adenocarcinoma (median survival: 11 vs. 26 months, $p < 0.001$) or squamous cell carcinoma (median survival: 19 vs. 30 months, $p = 0.003$) [34]. The median survival of patients with LC and IPF was shorter than that of the group without IPF in stage I (34 vs. 77 months, $p < 0.001$) and III of non-small cell carcinoma (NSCLC) (13 months vs. 18 months, $p = 0.013$). Median survival was similar in the IPF and the group without IPF with stage II (23 months vs. 28 months, $p = 0.142$) and stage IV of NSCLC (6 months vs. 7 months, $p = 0.220$) [34]. Among patients with SCLC, the median survival of the IPF and non-IPF groups was similar in both limited (16 months vs. 16 months, $p = 0.456$) and extensive stages of SCLC (6 months vs. 9 months, $p = 0.379$) [34]. In addition to cancer type and stage, morbidity and mortality are influenced by treatment modalities in all patients, but especially in patients with IPF and fILD.

iii. Pathogenesis of Cancer in ILD

The increased prevalence and accumulative incidence of lung cancer in fILD suggest that ILD may itself promote lung cancer development [14]. Specifically, in IPF, some molecular and genetic features of its pathogenesis and progression are linked to mechanism that favour development of malignancy [12]. Unfortunately, the evidence for pathogenesis of lung cancer in ILD patients is vague. The following hypotheses are drawn from studies in patients with fILD or lung cancer. These findings need further confirmation in ILD patients with lung cancer and should be considered carefully.

Histopathological studies in IPF, the archetype of fILD with a UIP pattern as the histological background, suggest that abnormal bronchiolar proliferation in fibrotic areas might be the preneoplastic lesion [35]. An immunohistochemistry study of 33 cases of LC arising in patients with IPF demonstrated that neoplastic cells express bronchial markers including the transcription factor 1 (TTF-1), napsin-A and surfactant protein A, expressed also in a minority of cases of adenocarcinoma [35].

Proteins involved in cell renewal of bronchial epithelium such as Δ Np63 and proteins promoting bronchiolar cells abnormal migration such as laminin-5-gamma2 chain and Hsp27 were found to be overexpressed in bronchiolo-alveolar junctions and in cells covering fibroblastic foci or honeycomb cysts [36].

Abnormal activation of the Wnt/ β catenin pathway was documented in fibrotic areas in lung samples obtained from patients with IPF and this pathway could be involved in squamous dysplasia and in promoting squamous carcinoma differentiation [37, 38]. Recently, single-cell sequencing and gene expression analyses have supported histopathological findings of proliferative bronchiolar structures or bronchiolisation in lung samples with UIP pattern [38]. Increased airway epithelial cells populations at the expense of the typical alveolar epithelial cell markers were found [39]. Moreover, airway basal cell populations (CK5/6+ and Δ Np63+) have been described in the surroundings of the fibroblast foci in a study of BAL cell expression in IPF patients [40].

One of the cardinal mechanisms that may promote bronchial precancerous lesions in IPF lungs is alveolar epithelial cell exhaustion [41]. Both intrinsic (e.g., genetic, aging) and environmental factors (e.g., smoking, pollution) contribute to alveolar stem cell dysfunction in patients with IPF. These cells express senescence markers and are unable to rebuild the lung parenchyma properly after endogenous or exogenous insults. However, they acquire a senescence associated secretory phenotype (SASP) inducing aberrant activation of important regulators of cell transformation, growth and migration signals and epithelial mesenchymal transition (EMT) [37, 38] such as Wnt/ β -catenin and Sonic hedgehog (Shh) pathways [42]. Along with formation of a fibrotic microenvironment [38], these processes lead to bronchial overgrowth, cancer cell development and progression [37]. In a subset of IPF patients, expression of membrane PD-L1 protein in alveolar and/or bronchiolar cells was recently documented confirming the pathogenetic role of EMT and reinforcing the links between IPF pathogenesis and carcinogenesis [43].

Atypical squamous cells are frequently found in honeycombing areas. Serpin B4 overexpression in these metaplastic cells was related to both TGF- β and Ki-67 overexpression and was higher in patients with foci of cancer/high-grade dysplasia showing that this pathway could be another important co-factor for cancer development in IPF lungs [44].

In addition, some genes under post-transcriptional control of miR-200 are overexpressed in bronchiolar fibro-proliferative lesions of IPF lungs that are microRNAs regulating EMT and tumour cell adhesion. This further suggests that activation of EMT might have a role in abnormal bronchiolar progression in these areas [45, 46].

Along with these typical fibrosis-related mechanisms, a genomic study carried out by Hwang *et al.* has provided a new perspective on the origin of LC in ILD [47]. The genomic profile of lung cancer associated with IPF showed a significantly higher prevalence of mutations in *TP53* and *BRAF* in their cohort, genes implicated in cell proliferation and survival, suggesting a genetic susceptibility to LC in patients with IPF [47].

In summary, bronchiolar hyperplastic-dysplastic cells are possibly the driver of lung cancer in ILD. Bronchiolisation of distal areas within UIP patterns is promoted by a pro-fibrotic microenvironment, and the mechanisms involved in fibrosis development may also activate molecular processes able to induce preneoplastic and in more advanced stages, cancerous lesions, as shown in Figure 1.

iv. Treatment of lung cancer in ILD patients

Lung cancer treatment is currently tailored to each individual according to the stage, type of cancer and the performance status of the patients. Lung cancer in ILD has some peculiarities which pose a challenge to care providers, especially in IPF patients. Patients with IPF are typically of older age, often smokers, and highly comorbid. The underlying ILD leads to reduced lung functional performance and respiratory capacity (i.e., reduced FVC and DLCO). Mortality is increased with increasingly severe lung function impairment, as judged by FVC, DLco, the composite physiologic index or the ILD-Gender Age Physiology index. In addition, underlying ILD predisposes to a risk of AE and, thus, increased mortality [33]. Therapeutic strategies for LC in patients with fILD need to be adapted according to the individual treatment risk and the prognosis of both LC and underlying ILD [48].

Early and late LC mortality in patients with ILD is increased after adjustment for confounding factors. Some of the reasons for early mortality are AE of the fILD related to surgery, irradiation, or anticancer drugs [49]. Late mortality may rather be due to LC progression or relapse, and also to ILD natural history [50]. Treatment options for NSCLC have improved dramatically over the last decade. An individual and personalised treatment approached of LC in patients with fILD is desirable.

An overview of modern therapeutic strategies for LC with fILD other than SCLC is illustrated in Table 1 and suggestions are summarised in Table 2. Next to surgical treatments for selected candidates, Stereotactic Body Radiation Therapy (SBRT) can be chosen for frail patients with early-stage cancer. Combination treatments or only chemotherapy/targeted anticancer drugs might be chosen for more advanced stages depending on overall individual frailty and age. The individual treatment options for SCLC and NSCLC are described below.

Small Cell Lung Cancer (SCLC) in fILD

Patients with SCLC and fILD respond well to standard treatment if they can tolerate chemotherapy. The prognosis of SCLC in patients with ILD is comparable to those without ILD [48].

In SCLC receiving chemotherapy the overall survival in patients with ILD was not inferior to that in patients without ILD. In ILD patients with an UIP pattern the overall survival was reduced compared to non-UIP, though not statistically significant [51].

Early-stage non-Small Cell Carcinoma (NSCLC) in fILD (stage I and II)

Surgery

Surgical options in NSCLC include lobar resection or anatomical sublobar resection, pneumonectomy or wedge resection depending on the tumour localisation, size, stage and morbidity. Lobar resection has a better prognosis than partial resection in early disease. In carefully selected patients, outcome can be improved by adjuvant chemotherapy. The factors determining better outcomes are lower stages than pIIA-IIIA (according to TNM 8th Classification) [52], better performance status score, younger age, and absence of comorbidities [53, 54]. In these situations, mortality at 5 years is reduced by 5 to 15%. In real-life, less than 60% of general LC patients receive adjuvant treatment [55, 56]. When surgery is not possible due to poor performance status score, early stage NSCLS (tumour <3cm) can alternatively be treated by SBRT [57].

Peri-operative mortality is increased in IPF patients undergoing cancer surgery [58]. Post-operative and surgery-related mortality are increased in IPF with a lower 5-year survival after pulmonary resection of NSCLC in IPF compared to non IPF [59]. The 5-year survival in patients with NSCLC was 43% in patients with IPF and 64.2% among those without IPF ($p < 0.001$). The disease-free survival was similar in the groups [60]. In a matched case control study from Korea, 33 patients with IPF who had undergone surgery were matched with 66 control patients who had undergone LC surgery. The

5-year survival rate was 38% for lung cancer patients with IPF and 73% for the control group ($p=0.001$) [61]. In a Japanese study with 870 LC patients undergoing surgery, 56 patients had IPF. Surgery-related mortality was higher in patients with LC and IPF than in patients with LC alone (7.1%vs 1.9%; $p=0.030$) [58]. One reason for increased mortality associated with surgery is acute ILD exacerbations, addressed later in the discussion of the role of antifibrotics in lung cancer treatment.

Radiotherapy

For patients with poor lung reserve or comorbidities, even in early NSCLC, surgical and chemotherapeutic options are limited. In a systematic review by Chen et al. [57] of patients with early-stage NSCLC and ILD, high levels of treatment related toxicity and ILD specific toxicity were documented in patients undergoing SBRT, Particle Beam Therapy (PBT) or Radio Frequency Ablation (RFA). Survival without treatment was 12 months. The *pro* or *cons* of undergoing potential toxic treatment versus best supportive care must be carefully considered by both clinicians and patients. A retrospective study by Onshi et al. in 242 patients with ILD and early-stage lung cancer receiving SBRT found the rate of severe radiation pneumonitis to be 12.4% [62]. The mortality rate was 6.9%. Some of the risk factors for poor outcome include $FVC < 70\%$, more than 10% of normal lung receiving radiation, performance status 2-4, presence of squamous cell carcinoma, clinical stage T2, as well as regular use of steroid before SBRT [62]. Very few data evaluate the efficacy and toxicity of conventional radiation therapy in patients with LC-ILD. Radiotherapy-induced pneumonitis can add to mortality in LC-IPF and contribute to the overall poor outcome in these patients [63]. The European Organization for Research and Treatment of Cancer (EORTC) recommends that conventional radiotherapy should be avoided for patients with LC-IPF [64].

Late-stage NSCLC

In advanced stages, lung cancer can be treated with chemotherapy, targeted therapy, and immunotherapy, in general. The few prospective or case-controlled cohorts contain limited number of patients (15 to 100) with advanced LC-fILD, amongst whom IPF is present in 25-100% of cases. Almost all studies were conducted with carboplatin [65–70]. Most studies evaluated carboplatin in combination with weekly paclitaxel (or nanoparticle albumin-bound, Nab-paclitaxel) [71–75], with less data on immune-check point inhibitors (ICI) [70, 76]. The results from these studies need to be interpreted with caution. The limited data-base shows an unexpectedly high proportion of response

rate (27-70%) in the previously cited studies. Response criteria such as tumour shrinkage have been defined to standardise response rate assessment [77]. In the respective studies, patients had good performance status, the histology is variable with a high proportion of stage IIIA-B receiving CT instead of surgery/radiotherapy, enriching the population of “good prognosis” cancer patients. Also, they did not include patients with poor lung volumes or low DLco. The progression free survival was 3.7 to 7.2 months with an overall survival of 5.4 to 19.4 months. AE was observed in 2.8 to 12% of cases.

Chemotherapy, Kinase Inhibitor and Immune Checkpoint Inhibitors

In retrospective studies, the overall survival was increased in LC patients (with or without ILD) receiving chemotherapy compared to patients who received palliative care, as shown in a cohort studying the effects of chemotherapy in patients with LC-ILD (specifically idiopathic interstitial pneumonias) [51]. Median survival time (MST) was 25.0 vs 1.8 months ($p = <0.001$). In patients receiving chemotherapy, the overall survival was reduced in ILD patients (MST: 10.9 months vs 25.0 months $p = 0.043$). In NSCLC, the overall survival was reduced in patients with ILD (MST: 10.6 vs 27.9 months $p = 0.008$) [51].

No randomised prospective controlled trial has evaluated the effects of chemotherapy on LC outcome in patients with fILD. In real life a lot of LC-fILD patients are of advanced age and have various comorbidities, increasing the risk of treatment. AE-ILD is an important complication of treatment. Thus, treatment options need to be tailored for individual cases, balancing individual risks and benefits. AE induced by chemotherapy in advanced LC-IPF increases the risk for mortality [69]. In a Japanese study of 69 patients, those with a UIP pattern on chest CT scan developed AE after chemotherapy more frequently than those with a non-UIP pattern (30% versus 8%, $p=0.005$) [69]. A study by Kanaji et al. observed that patients with ILD and IPF treated with paclitaxel/nab paclitaxel had few AE. Acute exacerbations in patients treated with docetaxel were seen in 18.4% and 20.8% of patients with ILD and IPF, respectively [78].

Two retrospective cohorts suggested that adding bevacizumab reduces the risk of ILD progressions or acute exacerbation even if ILD was related to chemotherapy [70, 79]. Bevacizumab is a monoclonal antibody against VEGF and has been used for NSCLC in combination with Paclitaxel [80]. Interestingly, VEGF plays a role in ILD progression and fibrosis development could inhibited in a

preclinical model of VEGF-A deficient alveolar type II cells in mice[81]. Of note, Nintedanib, used to reduce the IPF progression, is a well-known inhibitor of the receptor tyrosine kinase VEGFR [82].

In addition to standard chemotherapy, Kinase Inhibitors (KI) are now standard of care for advanced NSCLC with oncogene addiction [83]. However, drug-induced ILD is more frequent with KIs than with chemotherapy. Prior ILD is a risk factor for KI-associated ILD. Mortality rate for KI-induced ILD is high [84]. In the general population, ICI are the standard of care in 2nd line for advanced NSCLC, with Pembrolizumab, Atezolizumab and Cemiplimab being standard of care as 1st line treatment for advanced NSCLC with PD-L1 expression >50% or in combination with a double platinum chemotherapy in other fit patients (Pembrolizumab and Atezolizumab). In a phase II trial on Nivolumab for advanced NSCLC in fILD, 6 months progression free survival rate was 56%, response rate was 39%, and disease control rate was 72% [85] with a low frequency of AE and no treatment-related death. By contrast, another phase II trial with Atezolizumab showed an incidence of pneumonitis in patients with fILD of 29.4%, leading to early study closure. However, in this trial, the proportion of IPF patients was high. The objective response rate was 6.3 % [86]. A retrospective study confirmed increased incidence of pneumonitis in patients receiving Nivolumab [87]. A retrospective study from Japan comparing nivolumab versus pembrolizumab showed non-inferior outcomes with respect to progression free survival and overall survival [88]. In summary, ICI studies are scarce, mostly consisting of retrospective cohorts, with contradictory results, limited numbers of patients, confined to Asian countries and mostly investigating patients with IPF.

Palliative care

In addition to tumour-directed treatments, palliative care should be considered early in the treatment process. Palliative care medicine is often wrongly perceived as a terminal phase treatment [89]. It is centred on patient needs, providing comfort and symptom control.

fILD and LC are each fatal in isolation and their combination has a synergistic effect in increasing mortality and reducing quality of life. A review published by Naccache et al. summarises this grim scenario. In patients with LC and fILD after resection, a second LC is observed in 36% of cases [48]. In combined pulmonary fibrosis and emphysema (CPFE), 43% of patients with LC do not receive standard care because of underlying CPFE. In advanced fILD, 20 to 25% of patients are unable to receive chemotherapy due to frailty and 50% of patients receive only one type of chemotherapy [48].

v. Role of antifibrotics in ILD and cancer

Antifibrotics reduce AE due to cancer treatment

Cancer treatment-associated mortality, especially in patients undergoing surgical resection, can be attributed to AE. The incidence of post-operative AE was 6.4% in a single centre study from Tokyo [90]. In a multicentric data analysis from Japan post-operative AE of ILD occurred in 164 patients (9.3%) with an overall mortality rate of 44% [91]. The timing peak of AE was at day 4. 64% developed AE in the first 10 days post-surgery [91].

Risk factors for AE after surgical resection include type of surgery, elevated KL-6 levels, male sex, reduced vital capacity in %, history of AE, preoperative steroid use and a UIP pattern on CT [48, 92]. In patients with LC-ILD, surgical procedures have shown the strongest association with AE, possibly due to handling of the lungs, lymphatics and vasculature during the intervention [91]. The risk of AE increases according to the volume of lung removed with the highest risk for pneumonectomy and lowest risk for wedge resection. Minimally invasive surgery such as Video-assisted thoracoscopic surgery (VATS) does not reduce the risk of AE [93]. Controlling intra-operative intravenous fluid have shown to be protective for development of AE in IPF patients undergoing LC surgery [94]. A single centre study from Japan found high oxygen concentration with single lung ventilation and hyperventilation with high airway pressure increased the risk of AE in IIP patients undergoing surgical resection [95].

In a retrospective review of preoperative CT and histopathological examination in patients who underwent resection for LC, the incidence of clinical acute respiratory distress syndrome (ARDS, synonymous with AE in ILD patients), was 31.8% in patients with “Interstitial Pneumonia” defined histologically, which was strikingly higher than the 1.5% prevalence observed in the “Interstitial Pneumonia negative group” 1.5% [59]. This suggests that the histopathological presence of interstitial pneumonia trumps other risk factors for post-operative acute ARDS, manifesting clinically as breathlessness and histologically as diffuse alveolar damage [96]. An observational study by Oishi et al suggests that high SUV max in PET imaging in IIP area may predict both AE after lung resection and short-term survival [97]. Uneo et al noted that ILD Gender-Age-Physiology (GAP) Index can predict prognosis in patients with LC and ILD undergoing surgical resection [98].

The benefits of anti-fibrotic agents in patients with LC-ILD

Antifibrotic drugs have been observed to reduce AE in IPF. In the INPULSIS trials of Nintedanib in IPF, the frequency of AE was reduced in the active treatment arm [99], although data on this potential benefit of pirfenidone are less conclusive in the general IPF population. Paradoxically, studies of the benefits of anti-fibrotic agents in reducing AE prevalence in LC-ILD patients, following cancer interventions, are mostly confined to Pirfenidone.

The potential efficacy of peri-operative Pirfenidone in reducing the incidence of post-operative AE-IPF and, thus, reducing post-operative mortality has been explored in retrospective cohorts of LC patients undergoing resection surgery (summarized in Table 3) [100–103]. These studies have several limitations. Underpowered retrospective cohorts are subject to publication bias and to potential differences in standard of perioperative and post-operative care between active and inactive arms if open therapy is used. In two studies, a rigorous protocol for the duration of pre-operative Pirfenidone was used, raising the possibility that the whole operative protocol was more rigorous in this patient sub-group. It is clearly possible that baseline difference between treated and untreated groups might have separately influenced post-operative outcomes. Therefore, whilst the data from these studies are suggestive of a Pirfenidone protective effect, a prospective placebo-controlled study is required if peri-operative Pirfenidone is to become standard of care. It should be noted that all three studies were conducted in Japan with the possibility that genetic factors might limit the generalizability of the findings. Nintedanib has not been studied in this context, as Pirfenidone has been the anti-fibrotic therapy routinely used in Japan. In addition, Nintedanib has potential bleeding side effects due to anti-angiogenic properties that might complicate cancer treatment [104].

There is some evidence that anti-fibrotic therapy reduces the risk of radiation pneumonitis in animal studies but there is no compelling human data. In animal experiments, a study by Sun Y et al. found that oral Pirfenidone prevents radiation -induced interstitial fibrosis when administered in rats [105]. A study in 266 mice showed that Nintedanib administration diminishes histologic signs of radiation-induced lung damage [106]. A study by Qin W observed that Pirfenidone also protects against radiation induced pulmonary fibrosis in mice [107]. Human data are needed to establish proof of concept before a definitive trial.

Data are beginning to emerge that antifibrotic therapy may facilitate chemotherapy by reducing complications of chemotherapy. The prevalence of acute exacerbations with chemotherapy in LC/IPF is estimated as 10-30%. A study with Carboplatin plus Nab paclitaxel with and without Nintedanib demonstrated that addition of Nintedanib prolongs the interval to acute exacerbation [108]. In a study of 14 IPF patients with NSCLC receiving first line chemotherapy (carboplatin + paclitaxel) in combination with Pirfenidone, there were no acute exacerbations or adverse safety signals reported [109]. Although there are currently insufficient data to establish “proof of concept”, the potential importance of these observations fully justifies a high priority for larger prospective studies.

Direct effects of antifibrotics on cancer

Over the last decade, the treatment of fibrotic ILD has been revolutionised by the use of anti-fibrotic drugs that reduce fibrosis progression in IPF and other progressive fibrosing ILDs [110]. Pirfenidone and Nintedanib are currently the only approved anti-fibrotic drugs, with additional candidate anti-fibrotic therapies undergoing clinical trial evaluation. As the pathogenesis of ILD and LC includes overlapping pathways, it is theoretically possible that anti-fibrotic therapy has anti-neoplastic effects [12]. Interestingly, Nintedanib in association with docetaxel is an approved second-line cancer drug for selected NSCLC patients and has been used in patients with IPF and cancer [111].

Several reports show that Pirfenidone targets pathways implicated in lung cancer pathogenesis. Pirfenidone inhibits cancer fibroblasts, and enhances immune checkpoint inhibitor efficacy in mice [112]. *In vivo* studies confirm targeting of cancer fibroblasts and inhibition of fibroblasts and stroma cross talk [113]. Pirfenidone induces cell cycle arrest in human and mice cells and inhibits cancer proliferation [114]. *In vivo*, it interferes with the urokinase system and may influence the stability of tumour blood cells [115]. *In vivo*, it may revert epithelial to mesenchymal transition in lung adenocarcinoma [116]. However, human data are required for proof of concept.

Retrospective study data from 261 IPF patients with and without Pirfenidone showed LC incidence of 2.2% in the Pirfenidone group and 22% in the non-Pirfenidone group ($p < 0.001$) [117]. On multivariable analysis, LC incidence was lower in patients treated with Pirfenidone (HR=0.11, $p=0.003$) and higher in patients with concurrent emphysema (HR=3.22, $p=0.009$) [117]. However, these data, if confirmed, do not indicate that Pirfenidone prevents cancer genesis. LC manifests as a

pulmonary nodule after perhaps 30 tumour doubling times. If we assign average doubling time as four to six months, it follows that lung cancer is present for > 10 years by the time it is diagnosable [118]. Therefore, the above data suggest that Pirfenidone may slow cancer progression before it is clinically detectable. If so, it is possible that the lengthier survival achieved by anti-fibrotic therapy will not necessarily result in a major increase in the lung cancer burden.

The use of antifibrotic therapy for ILD in fILD patients with LC

In untreated patients diagnosed with lung cancer and ILD, there is no evidence that use of anti-fibrotic agents should differ from their use in ILD in general. If lung cancer is advanced, without the option of radical interventions, and the approach is broadly palliative, the introduction of anti-fibrotic drugs with the goal of slowing ILD progression is unlikely to be helpful and may reduce quality of life. However, this scenario aside, there are no data to suggest that ILD management should be modified. When a definite or working diagnosis of IPF is made, anti-fibrotic therapy may improve life expectancy with the added possibility, as discussed earlier, that AE triggered by resection surgery, chemotherapy or radiotherapy may be reduced in prevalence. When an alternative diagnosis to IPF is made, and ILD is overtly progressive, the documented benefits of anti-fibrotic therapy in progressively fibrotic ILD justify its use [7, 110, 119]. It should be acknowledged that patients with fibrotic ILD associated with LC were not included in these trials. However, the uniformity of treatment effects across a wide variety of non-IPF disorders in the INBUILD Nintedanib trial can reasonably be extrapolated to this group of patients. There are no data to suggest that anti-fibrotic therapy in patients with pre-existing ILD should be discontinued when LC is diagnosed. However, non-IPF patients managed with immunosuppressive therapy should ideally be discussed, case by case, with an oncologist, in view of the possible deleterious effects of these treatments in promulgating cancer progression.

5. Conclusion and Outlook

More and better designed studies are needed to determine the true incidence/prevalence of LC in fILD. Optimal treatment strategies need to be defined and evaluated. The development of centres of excellence for ILD and cancer has the potential to improve patient care. As most studies included IPF patients, future studies need to include CTD ILD and other ILDs.

Acknowledgements

Figure 1 was created with BioRender.com.

Figure 1: Pathomechanisms of lung cancer and fibrosing interstitial lung disease. Dysplastic bronchial cells accumulate near fibroblastic foci. SASP and stem cell exhaustion contribute to dysplastic bronchial cell development. Fibrotic processes including EMT, Wnt/ β -Catenin and Sonic Hedgehog pathways contribute to cancer development. Antifibrotic drugs inhibit fibrosis and might have potential effects on cancer.

References

- [1] Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis An Official ATS/ERS/JRS/ALAT Clinical practice guideline. *American Journal of Respiratory and Critical Care Medicine* 2018; 198: e44–e68.
- [2] Lynch JP, Saggar R, Weigt SS, et al. Usual interstitial pneumonia. *Seminars in respiratory and critical care medicine* 2006; 27: 634–651.
- [3] Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung Diseases. *New England Journal of Medicine* 2020; 383: 958–968.
- [4] Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. *American journal of respiratory and critical care medicine* 2007; 176: 636–643.
- [5] Miyashita K, Kono M, Saito G, et al. Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis. *The clinical respiratory journal* 2021; 15: 336–344.
- [6] Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. *The New England journal of medicine* 2011; 365: 1079–1087.
- [7] Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. *The Lancet Respiratory medicine* 2020; 8: 147–157.
- [8] Wollin L, Distler JHW, Redente EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. *European Respiratory Journal* 2019; 54 (3) 1900161.
- [9] Margaritopoulos GA, Antoniou KM, Wells AU. Comorbidities in interstitial lung diseases. *European Respiratory Review* 2017; 26 (143) 160027.
- [10] Noordzij M, Dekker FW, Zoccali C, et al. Measures of disease frequency: Prevalence and incidence. *Nephron - Clinical Practice* 2010; 115: c17–c20
- [11] Dong H, Robison LL, Leisenring WM, et al. Practice of Epidemiology Estimating the Burden of Recurrent Events in the Presence of Competing Risks: The Method of Mean Cumulative Count. *Am J Epidemiol.* 2015 Apr 1; 181(7):532-40.
- [12] Ballester B, Milara J, Cortijo J. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets. *International journal of molecular sciences.* 2019, 20, 593.
- [13] Brown SAW, Dobelle M, Padilla M, et al. Idiopathic Pulmonary Fibrosis and Lung Cancer. A Systematic Review and Meta-analysis. *Annals of the American Thoracic Society* 2019; 16: 1041–1051.
- [14] Lee HY, Lee J, Lee CH, et al. Risk of cancer incidence in patients with idiopathic pulmonary fibrosis: A nationwide cohort study. *Respirology* 2021; 26: 180–187.
- [15] le Jeune I, Gribbin J, West J, et al. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. *Respiratory medicine* 2007; 101: 2534–2540.
- [16] Yoon JH, Nourai M, Chen X, et al. Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease - Analysis of institutional and population data. *Respiratory Research* 2018 Oct 3; 19(1):195.
- [17] Krist AH, Davidson KW, Mangione CM, et al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA* 2021; 325: 962–970.

- [18] Brüske-Hohlfeld I, Möhner M, Pohlabein H, et al. Occupational lung cancer risk for men in Germany: results from a pooled case-control study. *American journal of epidemiology* 2000; 151: 384–395.
- [19] Watanabe Y, Kawabata Y, Koyama N, et al. A clinicopathological study of surgically resected lung cancer in patients with usual interstitial pneumonia. *Respiratory Medicine* 2017; 129: 158–163.
- [20] Benusiglio PR, Fallet V, Sanchis-Borja M, et al. Lung cancer is also a hereditary disease. *European respiratory review* 2021;30(162):210045.
- [21] Yoo H, Jeong B-H, Jin Chung M, et al. Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study. *BMC Pulm Med.* 2019 ;19(1):149.
- [22] Jin Song M, Yee Kim S, Suk Park M, et al. A nationwide population-based study of incidence and mortality of lung cancer in idiopathic pulmonary fibrosis. *Scientific Reports* 2021; 11: 2596.
- [23] Choi W il, Park SH, Park BJ, et al. Interstitial Lung Disease and Lung Cancer Development: A 5-Year Nationwide Population-Based Study. *Cancer research and treatment* 2018; 50: 374–381.
- [24] Hironaka M, Fukayama M. Pulmonary fibrosis and lung carcinoma: a comparative study of metaplastic epithelia in honeycombed areas of usual interstitial pneumonia with or without lung carcinoma. *Pathology international* 1999; 49: 1060–1066.
- [25] Kawai T, Yakumaru K, Suzuki M, et al. Diffuse interstitial pulmonary fibrosis and lung cancer. *Acta pathologica japonica* 1987; 37: 11–19.
- [26] Ozawa Y, Suda T, Naito T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. *Respirology (Carlton, Vic)* 2009; 14: 723–728.
- [27] Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. *Chest* 2015; 147: 157–164.
- [28] Watanabe S, Saeki K, Waseda Y, et al. Lung cancer in connective tissue disease-associated interstitial lung disease: clinical features and impact on outcomes. *Journal of thoracic disease* 2018; 10: 799–807.
- [29] Kawasaki H, Nagai K, Yokose T, et al. *Clinicopathological Characteristics of Surgically Resected Lung Cancer Associated With Idiopathic Pulmonary Fibrosis.* *J Surg Oncol* 2001;76(1):53-7.
- [30] Tzouvelekis A, Karampitsakos T, Gomatou G, et al. Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Greece. *Pulmonary pharmacology & therapeutics* 2020;60: 101880.
- [31] Karampitsakos T, Tzilas V, Tringidou R, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. *Pulmonary pharmacology & therapeutics* 2017; 45: 1–10.
- [32] JafariNezhad AR, YektaKooshali MH. Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. *PloS one* 2018;13(8):e0202360.
- [33] Gibiot Q, Monnet I, Levy P, et al. Interstitial Lung Disease Associated with Lung Cancer: A Case-Control Study. *Journal of clinical medicine* 2020;9(3):700.
- [34] Kim HC, Lee S, Song JW. Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients. *Scientific reports* 2021;11(1):8312.

- [35] Caliò A, Lever V, Rossi A, et al. Increased frequency of bronchiolar histotypes in lung carcinomas associated with idiopathic pulmonary fibrosis. *Histopathology* 2017; 71: 725–735.
- [36] Chilosi M, Poletti V, Murer B, et al. Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63. *Laboratory investigation; a journal of technical methods and pathology* 2002; 82: 1335–1345.
- [37] Chilosi M, Poletti V, Zamò A, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. *The American journal of pathology* 2003; 162: 1495–1502.
- [38] Renzoni EA, Poletti V, Mackintosh JA. Disease pathology in fibrotic interstitial lung disease: is it all about usual interstitial pneumonia? *Lancet (London, England)* 2021; 398: 1437–1449.
- [39] Adams TS, Schupp JC, Poli S, et al. Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis. *Science advances* 2020 ;6(28):eaba1983.
- [40] Prasse A, Binder H, Schupp JC, et al. BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis. *American journal of respiratory and critical care medicine* 2019; 199: 622–630.
- [41] Chilosi M, Doglioni C, Murer B, et al. Epithelial stem cell exhaustion in the pathogenesis of idiopathic pulmonary fibrosis. *Sarcoidosis, vasculitis, and diffuse lung diseases: official journal of WASOG* 2010; 27: 7–18.
- [42] Froidure A, Marchal-Duval E, Homps-Legrand M, et al. Chaotic activation of developmental signalling pathways drives idiopathic pulmonary fibrosis. *European respiratory review: an official journal of the European Respiratory Society* 2020; 29: 1–13.
- [43] Kronborg-white S, Madsen LB, Bendstrup E, et al. PD-L1 Expression in Patients with Idiopathic Pulmonary Fibrosis. *Journal of clinical medicine* 2021;10(23):5562.
- [44] Calabrese F, Lunardi F, Balestro E, et al. Serpin B4 isoform overexpression is associated with aberrant epithelial proliferation and lung cancer in idiopathic pulmonary fibrosis. *Pathology* 2012; 44: 192–198.
- [45] Chilosi M, Caliò A, Rossi A, et al. Epithelial to mesenchymal transition-related proteins ZEB1, β -catenin, and β -tubulin-III in idiopathic pulmonary fibrosis. *Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc* 2017; 30: 26–38.
- [46] Moimas S, Salton F, Kosmider B, et al. miR-200 family members reduce senescence and restore idiopathic pulmonary fibrosis type II alveolar epithelial cell transdifferentiation. *ERJ open research* 2019;5(4):00138.
- [47] Hwang JA, Kim D, Chun SM, et al. Genomic profiles of lung cancer associated with idiopathic pulmonary fibrosis. *The Journal of pathology* 2018; 244: 25–35.
- [48] Naccache JM, Gibiot Q, Monnet I, et al. Lung cancer and interstitial lung disease: a literature review. *Journal of thoracic disease* 2018; 10: 3829–3844.
- [49] King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. *The Lancet Respiratory medicine* 2017; 5: 72–84.
- [50] Tzouvelekis A, Spagnolo P, Bonella F, et al. Patients with IPF and lung cancer: diagnosis and management. *The Lancet Respiratory medicine* 2018; 6: 86–88.
- [51] Kashiwabara K SHFSTSAR. Difference in benefit of chemotherapy between small cell lung cancer patients with interstitial pneumonia and patients with non-small cell lung cancer. *Anticancer Res* 2015 Feb;35(2):1065-71 .

- [52] Detterbeck FC, Boffa DJ, Kim AW, et al. The Eighth Edition Lung Cancer Stage Classification. *CHEST* 2017; 151: 193–203.
- [53] Homma S, Bando M, Azuma A, et al. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. *Respiratory investigation* 2018; 56: 268–291.
- [54] Ogura T, Takigawa N, Tomii K, et al. Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. *Respiratory investigation* 2019; 57: 512–533.
- [55] Toubat O, Atay SM, Kim AW, et al. Disparities in Guideline-Concordant Treatment for Pathologic N1 Non-Small Cell Lung Cancer. *The Annals of thoracic surgery* 2020; 109: 1512–1520.
- [56] Barni S, Maiello E, di Maio M, et al. Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. *Lung cancer (Amsterdam, Netherlands)* 2015; 90: 234–242.
- [57] Chen H, Senan S, Nossent EJ, et al. Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review. *International Journal of Radiation Oncology Biology Physics* 2017; 98: 622–631.
- [58] Watanabe A, Higami T, Ohori S, et al. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? *The Journal of thoracic and cardiovascular surgery* 2008;136(5):1357-63, 1363.
- [59] Saito H, Minamiya Y, Nanjo H, et al. Pathological finding of subclinical interstitial pneumonia as a predictor of postoperative acute respiratory distress syndrome after pulmonary resection. *European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery* 2011; 39: 190–194.
- [60] Kawasaki H, Nagai K, Yoshida J, et al. Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis. *Journal of surgical oncology* 2002; 81: 33–37.
- [61] Lee T, Park JY, Lee HY, et al. Lung cancer in patients with idiopathic pulmonary fibrosis: clinical characteristics and impact on survival. *Respiratory medicine* 2014; 108: 1549–1555.
- [62] Onishi H, Yamashita H, Shioyama Y, et al. Stereotactic Body Radiation Therapy for Patients with Pulmonary Interstitial Change: High Incidence of Fatal Radiation Pneumonitis in a Retrospective Multi-Institutional Study. *Cancers* 2018;10(8):257.
- [63] Kim H, Yoo H, Pyo H, et al. Impact Of Underlying Pulmonary Diseases On Treatment Outcomes In Early-Stage Non-Small Cell Lung Cancer Treated With Definitive Radiotherapy. *International journal of chronic obstructive pulmonary disease* 2019; 14: 2273–2281.
- [64] de Ruyscher D, Faivre-Finn C, Moeller D, et al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. *Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology* 2017; 124: 1–10.
- [65] Okuda K, Hirose T, Oki Y et al. Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease. *Anticancer Res* 2012 Dec;32(12):5475-80.
- [66] Watanabe N, Niho S, Kirita K, et al. Vinorelbine and cisplatin in patients with advanced non-small cell lung cancer with interstitial pneumonia. *Anticancer Research* 2015; 35: 1697–1702.


- [67] Kinoshita T, Azuma K, Sasada T, et al. Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia. *Oncology letters* 2012; 4: 477–482.
- [68] Choi MK, Hong JY, Chang W, et al. Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease. *Cancer Chemotherapy and Pharmacology* 2014; 73: 1217–1225.
- [69] Kenmotsu H, Naito T, Kimura M, et al. Therisk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. *Journal of Thoracic Oncology* 2011; 6: 1242–1246.
- [70] Enomoto Y, Kenmotsu H, Watanabe N, et al. Efficacy and safety of combined carboplatin, paclitaxel, and bevacizumab for patients with advanced non-squamous non-small cell lung cancer with pre-existing interstitial lung disease: A retrospective multi-institutional study. *Anticancer Research* 2015; 35: 4259–4264.
- [71] Shukuya T, Ishiwata T, Hara M, et al. Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease. *Anticancer Res* 2010 Oct;30(10):4357-61.
- [72] Minegishi Y, Sudoh J, Kuribayashi H, et al. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. *Lung cancer (Amsterdam, Netherlands)* 2011; 71: 70–74.
- [73] Asahina H, Oizumi S, Takamura K, et al. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302). *Lung cancer (Amsterdam, Netherlands)* 2019; 138: 65–71.
- [74] Kenmotsu H, Yoh K, Mori K, et al. Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease. *Cancer science* 2019; 110: 3738–3745.
- [75] Fukuizumi A, Minegishi Y, Omori M, et al. Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study. *International journal of clinical oncology* 2019; 24: 1543–1548.
- [76] Shimizu R, Fujimoto D, Kato R, et al. The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease. *Cancer chemotherapy and pharmacology* 2014; 74: 1159–1166.
- [77] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *European journal of cancer (Oxford, England : 1990)* 2009; 45: 228–247.
- [78] Kanaji N, Tadokoro A, Kita N, et al. Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival. *Journal of cancer research and clinical oncology* 2016; 142: 1855–1865.
- [79] Hamada S, Ichiyasu H, Ikeda T, et al. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer. *BMC pulmonary medicine*, 2019. 2019;19(1):72.
- [80] Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *The New England journal of medicine* 2006; 355: 2542–2550.
- [81] Barratt SL, Blythe T, Jarrett C, et al. Differential Expression of VEGF-A xxx Isoforms Is Critical for Development of Pulmonary Fibrosis. *American journal of respiratory and critical care medicine* 2017; 196: 479–493.

- [82] Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. *The European respiratory journal* 2015; 45: 1434–1445.
- [83] Tsakonas G, Ekman S. Oncogene-addicted non-small cell lung cancer and immunotherapy. *Journal of thoracic disease* 2018; 10: S1547–S1555.
- [84] Saito Y, Gemma A. Current status of DILD in molecular targeted therapies. *International journal of clinical oncology* 2012; 17: 534–541.
- [85] Fujimoto D, Yomota M, Sekine A, et al. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial. *Lung cancer (Amsterdam, Netherlands)* 2019; 134: 274–278.
- [86] Ikeda S, Kato T, Kenmotsu H, et al. A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2020; 15: 1935–1942.
- [87] Kanai O, Kim YH, Demura Y, et al. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. *Thoracic cancer* 2018; 9: 847–855.
- [88] Tasaka Y, Honda T, Nishiyama N, et al. Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease. *Lung cancer (Amsterdam, Netherlands)* 2021; 155: 120–126.
- [89] Kreuter M, Bendstrup E, Russell AM, et al. Palliative care in interstitial lung disease: living well. *The Lancet Respiratory medicine* 2017; 5: 968–980.
- [90] Goto T, Maeshima A, Oyamada Y, et al. Idiopathic pulmonary fibrosis as a prognostic factor in non-small cell lung cancer. *Int J Clin Oncol.* 2014;19(2):266-273.
- [91] Sato T, Teramukai S, Kondo H, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. *The Journal of thoracic and cardiovascular surgery*; 2014;147(5):1604-1611.
- [92] Sato T, Kondo H, Watanabe A, et al. A simple risk scoring system for predicting acute exacerbation of interstitial pneumonia after pulmonary resection in lung cancer patients. *General Thoracic and Cardiovascular Surgery* 2015; 63: 164–172.
- [93] Miyajima M, Watanabe A, Sato T, et al. What factors determine the survival of patients with an acute exacerbation of interstitial lung disease after lung cancer resection? *Surgery today* 2018; 48: 404–415.
- [94] Mizuno Y, Iwata H, Shirahashi K, et al. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer *Cardiothorac Surg.* 2012;41(6):e161-e165.
- [95] Sakamoto S, Homma S, Mun M, et al. Acute Exacerbation of Idiopathic Interstitial Pneumonia Following Lung Surgery in 3 of 68 Consecutive Patients: A Retrospective Study. *Intern Med.* 2011;50(2):77-85.
- [96] Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. *The New England journal of medicine* 2017; 377: 562–572.
- [97] Oishi H, Sakurada A, Notsuda H, et al. Correlation between preoperative 18 F-FDG PET/CT findings and postoperative short-term prognosis in lung cancer patients with idiopathic interstitial pneumonia after lung resection. *Respiratory investigation* 2021; 59: 106–113.
- [98] Ueno F, Kitaguchi Y, Shiina T, et al. The Interstitial Lung Disease-Gender-Age-Physiology Index Can Predict the Prognosis in Surgically Resected Patients with Interstitial Lung Disease

and Concomitant Lung Cancer. *Respiration; international review of thoracic diseases* 2020; 99: 9–18.

- [99] Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *The New England journal of medicine* 2014; 370: 2071–2082.
- [100] Iwata T, Yoshida S, Fujiwara T, et al. Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis. *Ann Thorac Surg.* 2016; 102: 1905–1910.
- [101] Iwata T, Yoshino I, Yoshida S, et al. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study). *Respiratory Research* 2016;17(1):90.
- [102] Sekihara K, Aokage K, Miyoshi T, et al. Perioperative pirfenidone treatment as prophylaxis against acute exacerbation of idiopathic pulmonary fibrosis: a single-center analysis. *Surgery today* 2020; 50: 905–911.
- [103] Kanayama M, Mori M, Matsumiya H, et al. Perioperative pirfenidone treatment for lung cancer patients with idiopathic pulmonary fibrosis. *Surgery Today* 2020; 50: 469–474.
- [104] Kolonics-Farkas AM, Šterclová M, Mogulkoc · Nesrin, et al. Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE. *Drug Safety* 2020; 43: 971–980.
- [105] Sun YW, Zhang YY, Ke XJ, et al. Pirfenidone prevents radiation-induced intestinal fibrosis in rats by inhibiting fibroblast proliferation and differentiation and suppressing the TGF- β 1/Smad/CTGF signaling pathway. *European journal of pharmacology* 2018; 822: 199–206.
- [106] de Ruyscher D, Granton PV, Lieuwes NG, et al. Nintedanib reduces radiation-induced microscopic lung fibrosis but this cannot be monitored by CT imaging: A preclinical study with a high precision image-guided irradiator. *Radiotherapy and Oncology* 2017; 124: 482–487.
- [107] Qin W, Liu B, Yi M, et al. Antifibrotic Agent Pirfenidone Protects against Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model. *Radiation research* 2018; 190: 396–403.
- [108] Otsubo K, Kishimoto J, Kenmotsu H, et al. Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. *Clinical lung cancer* 2018; 19: e5–e9.
- [109] Yamamoto Y, Yano Y, Kuge T, et al. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study. *Thoracic Cancer* 2020; 11: 3317–3325.
- [110] Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. *The Lancet Respiratory medicine* 2020; 8: 453–460.
- [111] Bosch ME, Díez RA, Agudo SG, et al. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report. *Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria* 2016; 40: 316–327.
- [112] Qin W, Zou J, Huang Y, et al. Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice. *Oncoimmunology*; 2020; 9(1): 1824631.

- [113] Fujiwara A, Funaki S, Fukui E, et al. Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer. *Scientific reports* 2020;10(1):10900.
- [114] Marwitz S, Turkowski K, Nitschkowski D, et al. The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC. *Frontiers in oncology* 2020; 9: 1550.
- [115] Krämer M, Markart P, Drakopanagiotakis F, et al. Pirfenidone inhibits motility of NSCLC cells by interfering with the urokinase system. *Cellular signalling* 2020; 65:109432.
- [116] Kurimoto R, Ebata T, Iwasawa S, et al. Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma. *Oncology letters* 2017; 14: 944–950.
- [117] Miura Y, Saito T, Tanaka T, et al. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. *Respiratory investigation* 2018; 56: 72–79.
- [118] Heuvelmans MA, Vliegenthart R, de Koning HJ, et al. Quantification of growth patterns of screen-detected lung cancers: The NELSON study. *Lung Cancer* 2017; 108: 48–54.
- [119] Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. *The Lancet Respiratory medicine* 2021; 9: 476–486.




	Cancer cell		Fibroblast		Bronchiolar dysplastic/hyperplastic cell		Type II pneumocyte	HSP=Heat Shock protein, SASP=Senescence Associated Secretory Phenotype TGFβ=Transforming Growth Factorβ
---	-------------	---	------------	---	--	---	--------------------	---

Table 1: A proposal for adapted modern therapeutic strategies for LC fILD other than SCLC.

Treatment	Stage I-IB	Stage IIA-IIIA	Stage IIIB/C	Stage IV		
Eligibility	Age, PS, FEV ₁ /DLCO, comorbidities			Age, PS, histology, comorbidities, 'auto-immunity'		
Biomarkers	NA	NA	NA	addiction (ADC)	PD-L1 ≥50%	PD-L1 <50%
	<ul style="list-style-type: none"> • Specific eligibility criteria for f-ILD: UIP vs others, CT-scan extension grading, FCV and DLCO evaluation, ILD-GAP index • Consider introduction of an anti-fibrotic drug 					
Standard	Lobectomy VATS No adjuvant CT		Treat as Stage IV?	Carboplatin weekly (nab-)paclitaxel (± bevacizumab)	Carboplatin weekly (nab-)paclitaxel (± bevacizumab)	Carboplatin weekly (nab-)paclitaxel (± bevacizumab)
				Nivolumab/pembrolizumab 2 nd line?		
Option/not fit	SBRT Sublobar resection	Treat as Stage IV?		Treat as Stage IV?	Kinase inhibitors?	Mono-CT paclitaxel, vinorelbine, pemetrexed
Frail/oldest patients/PS2	SBRT	Palliative care	Palliative care	Kinase inhibitor	Palliative care	Palliative care

PS: performance status; FEV₁: forced expiratory volume in 1 second; DLCO: diffusion linear of carbon monoxide; ADC: adenocarcinoma; f-ILD: fibrosing interstitial lung disease; UIP: usual interstitial pneumonia; FCV: forced vital capacity; GAP: gender, age, physiology; VATS: video assisted thoracoscopic surgery; CT: chemotherapy; SBRT: stereotactic body radiotherapy.

Table 2: Suggestions for treatment of LC in fILD

Suggestions based on the available studies are
1. The choice of treatment with CT should be carefully made by risk-benefit balance. Patient selection and careful counselling are crucial.
2. Carboplatin plus weekly (nab-)Paclitaxel for 4 (or 6) cycles remains the 1 st line standard therapy in fit NSCLC fILD patients without maintenance therapy.
3. Addition of Bevacizumab should be considered in fit non-squamous NSCLC
4. Vinorelbine (squamous) and Pemetrexed (adenocarcinoma) monotherapy should be administered in 2 nd line setting.
5. Carboplatin Etoposide for 4 cycles (or 6 cycles) remain the standards of care for SCLC
6. Really not recommended drugs (gemcitabine and docetaxel)

Table 3: Core features of studies of post-operative outcomes, comparing patients treated and not treated with peri-operative Pirfenidone (poPirf)

	Cohort size, treated and untreated arms	Study design	Post-operative AEIPF	Post-operative mortality
Iwata TK et al [101]	n=50 poPirf, n=33 No Px, n=17	Retrospective poPirf for 4 weeks before and after surgery	Reduction in AEIPF with poPirf at 30 days (0% vs 10.5%, p=0.07) and at 90 days (3.2% vs 21.1%, p=0.04)	IPF progression-free survival curves difference between groups was statistically marginal (p= 0.0676), better in the poPirf group. poPirf was not significantly, but was numerically, associated with better IPF progression-free survival.
Sekihara K et al [103]	n=56 poPirf, n=36 No PPT, n=20	Retrospective poPirf for 4 weeks before surgery, “longer periods” after surgery	Reduction in AEIPF with poPirf (8%) compared with no poPirf (20%) Non-significant trend (p=0.21)	Reduced mortality in poPirf group (p=0.04)
Kanayama M et al [104]	n=100 poPirf, n=28 No poPirf, n=72	Retrospective Not stated in abstract, need to extract article	No effect in low-risk group Reduction in AEIPF with poPirf in high-risk group at 30 days (p=0.11) and at 90 days (p<0.05)	Disease specific death (including due to AE): No significant difference at 1 year (83% in poPirf and 83.7% in non poPirf) or 3 years (66.4% in poPirf and 47.8 % in non poPirf) (p = 0.481) Progression free survival: No significant difference at 1 year (61.5% in the poPirf and 55.4% in non-poPirf groups) or 3-year (46.1% in the poPirf and 42.8% in non-poPirf groups) (p = 0.364).

AEIPF:Acute Exacerbation of Idiopathic Pulmonary Fibrosis; IPF:Idiopathic Pulmonary Fibrosis ;

Table 4: Current role of anti-fibrotic drugs in LC and fILD

Statement	Current status
Improved outcomes by improving fibrotic ILD outcomes	definite effect
May improve outcomes by protecting against AE with LC treatments: <ul style="list-style-type: none"> - cancer resection - chemotherapy - radiotherapy 	proof of concept attractive hypothesis hypothesis
May have worthwhile stand-alone anti-tumour effects <ul style="list-style-type: none"> - in vitro and animal data - reduced occurrence of cancer in pirfenidone-treated patients - anti-tumour effects in NSCLC with nintedanib 	attractive hypothesis proof of concept? proof of concept? attractive hypothesis
May also increase the incidence of LC/FILD due to prolonged survival	